EU205 / Eutilex - LARVOL DELTA

Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST (PRNewswire) - "Therapeutic Solutions International, Inc...announced...the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies....Eutilex has developed an autologous immunotherapy for tumors which unleash the endogenous ability of T cells to selectively kill tumor cells, even in solid tumors, which will be commercially developed in the US by Eutilogics."

Licensing / partnership • Oncology

Eutilex (263050) R&D momentum to grow stronger, corporate value rise (Maekyung Media Group) - "T-cell therapy AppB&T is in phase 1/2 clinical trial for patients with NK/T lymphoma...Patient administration is expected to begin in early 21st, and data is expected to be released in the second half...Researchers' clinical results will be presented at AACR (American Cancer Society) in April 21. WiT&T...is undergoing phase 1 clinical trials for patients with malignant brain tumors. The results are expected to be announced at the ASCO (American Society of Clinical Oncology) held in June 21. In addition, TAST, a next-generation T-cell therapy technology, is scheduled to apply for a phase 1 clinical trial IND in the second half of 21..."

Enrollment status • IND • New P1 trial • P1 data • P1/2 data • Brain Cancer • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma